Sort   by:  
 Page size 
UnknownTocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8084355 | biostudies-literature
UnknownOutcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.
Not available
S-EPMC10278789 | biostudies-literature
UnknownAntibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Not available
S-EPMC8927425 | biostudies-literature
UnknownNeutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Not available
S-EPMC9757903 | biostudies-literature
UnknownStratified analyses refine association between TLR7 rare variants and severe COVID-19.
Not available
S-EPMC11320601 | biostudies-literature
UnknownManagement of Coronary Disease in Patients with Advanced Kidney Disease.
Not available
S-EPMC7274537 | biostudies-literature
UnknownGWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19.
Not available
S-EPMC10208981 | biostudies-literature
UnknownHealth Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease.
Not available
S-EPMC7255621 | biostudies-literature
UnknownEfficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Not available
S-EPMC5731244 | biostudies-literature
UnknownWhole-genome sequencing reveals host factors underlying critical COVID-19.
Not available
S-EPMC9259496 | biostudies-literature
Sort   by:  
 Page size